![](https://i0.wp.com/glhf.org/wp-content/uploads/2023/02/Gene-therapy-906x453-1-1.jpg?resize=906%2C453&ssl=1)
First Patient Dosed with Hemophilia Gene Therapy Candidate ASC618
The first patient has been dosed in ASC Therapeutics clinical trial of ASC618, the company’s investigational AAV8 vector-based gene therapy for patients with severe and moderately severe hemophilia A.
Source: National Bleeding Disorders Foundation, December 2023